{"id":547724,"date":"2021-06-15T14:00:01","date_gmt":"2021-06-15T14:00:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=547724"},"modified":"2021-06-15T14:00:01","modified_gmt":"2021-06-15T14:00:01","slug":"er-her2ve-breast-cancer-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-eisai-g1-therapeutics-genetech-roche-sanofi-astrazeneca-and-many-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/er-her2ve-breast-cancer-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-eisai-g1-therapeutics-genetech-roche-sanofi-astrazeneca-and-many-others_547724.html","title":{"rendered":"ER+\/ HER2-ve Breast Cancer Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Eisai, G1 Therapeutics, Genetech, Roche, Sanofi, AstraZeneca and Many Others"},"content":{"rendered":"
\"ER+\/<\/a><\/p>\n
\n
HER2-ve Breast Cancer Pipeline<\/div>\n<\/div>\n<\/div>\n

Breast cancer<\/a><\/strong> is a disease in which cells in the breast grow out of control. There are different kinds of breast cancer. The kind of breast cancer depends on which cells in the breast turn into cancer. Most breast cancers express the estrogen receptor (ER) receptor and are negative for the human epidermal growth factor receptor 2 (HER2) receptor. The backbone of their systemic therapy consists of hormonal therapies that block the function of ER through various mechanisms. These include blockade of the receptor itself in breast cancer cells, blockade of the production of its major ligand, estradiol, or degradation of the receptor. However, a subset of ER+\/HER2− breast cancers, mostly corresponding to the genomic luminal B genotype, are resistant to hormonal manipulations from the outset of therapies.<\/p>\n

DelveInsight’s, “ER+\/ HER2-ve Breast Cancer Pipeline Insight, 2021<\/strong>” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs<\/strong> in ER+\/ HER2 -ve Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n

 <\/p>\n

Request for free Sample Report: https:\/\/www.delveinsight.com\/sample-request\/er-her2-ve-breast-cancer-pipeline-insight<\/a><\/strong><\/p>\n

 <\/p>\n

ER+\/ HER2-ve Breast Cancer Key Players:<\/strong><\/p>\n